Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epinastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 12/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.94 |
| ▸ | HTR1A | P08908 | 3/20 | 0.94 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.94 |
| ▸ | DRD1 | P21728 | 2/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.94 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.94 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.94 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.94 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.94 |
| ▸ | HTR2A | P28223 | 15/20 | 0.43 |
| ▸ | HTR2C | P28335 | 12/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epinastine SCHEMBL29945140 | 0.97 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL18794 | 0.97 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL357588 | 0.97 | ADRA1A (1.00) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL3989750 | 0.96 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL30678575 | 0.96 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL4292213 | 0.96 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122749 | 0.96 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL122751 | 0.96 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL3989748 | 0.96 | ADRA1A (0.97) | ADRA1AADRA2AHTR1AOPRM1DRD1 | |
| Epinastine SCHEMBL16093961 | 0.87 | ADRA1A (0.81) | ADRA1AADRA2AHTR1AOPRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-224271187-U | Reaction tank for epinastine hydrochloride processing | WUHAN CALMLAND PHARMACEUTICALS Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-119258073-A | Ophthalmic composition for inhibiting deterioration of soft contact lens | 参天制药株式会社 | 2025-01-07 | — | — | CN | claimed |
| CN-115397430-B | Aqueous compositions containing epinastine or salts thereof | 参天制药株式会社 | 2024-11-15 | — | — | CN | claimed |
| WO-2024135837-A1 | EPINASTINE-CONTAINING AQUEOUS COMPOSITION FOR IMPROVING TISSUE TRANSFERABILITY AND PRESERVATIVE EFFECT | 参天製薬株式会社 | 2024-06-27 | — | — | WO | claimed |
| CN-118021984-A | Compound external preparation, preparation method and application thereof | 南方医科大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117659019-A | Preparation method of epinastine impurity | 南京科默生物医药有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-20240074973-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-03-07 | — | — | US | claimed |
| CN-117427042-B | Preparation method of epinastine hydrochloride tablet | 泊诺(天津)创新医药研究有限公司 | 2024-03-05 | — | — | CN | claimed |
| CN-117554539-A | Method for determining epinastine hydrochloride related substances | 广州润尔眼科生物科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-117427042-A | Preparation method of epinastine hydrochloride tablet | 泊诺(天津)创新医药研究有限公司 | 2024-01-23 | — | — | CN | claimed |
| EP-1452177-A1 | Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent | Boehringer Ingelheim International GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| EP-1448204-A1 | NEW DRY AND AQUEOUS EPINASTINE-SYRUP-FORMULATION | Boehringer Ingelheim International GmbH (DE) | 2004-08-25 | — | — | EP | claimed |
| US-20030228359-A1 | Pharmaceutical formulations containing epinastine, belladonna, and pseudoephedrine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | claimed |
| WO-2003037350-A1 | NEW DRY AND AQUEOUS EPINASTINE-SYRUP-FORMULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-05-08 | — | — | WO | claimed |
| EP-1237892-B1 | METHOD FOR PRODUCING EPINASTINE HYDROCHLORIDE IN THE HIGH-MELTING CRYSTAL MODIFICATION | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-04-23 | — | — | EP | claimed |
| US-20030050303-A1 | Solutions containing epinastin | BOEHRINGER INGELHEIM PHARMA GMBH (DE) | 2003-03-13 | — | — | US | claimed |
| CN-1402728-A | Process for producing epinastine hydrochloride in high-melting crystal modification | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-03-12 | — | — | CN | claimed |
| US-6403790-B1 | SUSPENDING AND DISSOLVING EPINASTINE BASE IN WATER BY ADDING AQUEOUS HYDROCHLORIC ACID AT SPECIFIED PH, EXTRACTING SOLUTION OBTAINED WITH ORGANIC WATER-IMMISCIBLE SOLVENT, REMOVING SOLVENT, ADJUSTING PH TO PRECIPITATE PRODUCT, DRYING | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-11 | — | — | US | claimed |
| WO-2002020018-A1 | TABLETS CONTAINING EPINASTINE MANUFACTURED BY DIRECT COMPRESSION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-03-14 | — | — | WO | claimed |
| WO-2000000179-A1 | SOLID DISPERSED PREPARATION OF POORLY WATER-SOLUBLE DRUG CONTAINING OIL, FATTY ACID OR MIXTURES THEREOF | WON JIN BIOPHARMA CO., LTD. (KR) | 2000-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074973-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF | ASAH2, ASAH1, ACER2 | HRH1 1620/4885ADRA1A 1318/4885ADRA2A 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.